Drugs / CAR-T therapy for nectin4-positive malignant solid tumor
CAR-T therapy for nectin4-positive malignant solid tumor
Cell therapy targets FAP, NECTIN4 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03932565 | Feb 2019 → Jun 2021 | high grade malignant neoplasm | The Sixth Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T therapy for nectin4-positive malignant solid tumor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03932565 ↗ |
| Action | Deplete | “use the patient's own immune cells to clear cancer cells” NCT03932565 ↗ |
| Modality | Cell therapy | “fourth-generation CAR-T cells” NCT03932565 ↗ |
| Route | Intravenous | “Intravenous minimally invasive surgery” NCT03932565 ↗ |
| Target | FAP | “Nectin4/FAP-targeted” NCT03932565 ↗ |
| Target | NECTIN4 | “Nectin4/FAP-targeted” NCT03932565 ↗ |